Impact of antithrombin III on hepatic and intestinal microcirculation in experimental liver cirrhosis and bowel inflammation: An in vivo analysis

Table 4 Data of blood samples taken at the end of experiments (mean±SD)

	Cirrhosis	Cirrhosis and IBD	ATIII treatment group (cirrhosis and IBD)	Controls
ASOT (U/L)	63.67±10.42a	109.5±39.18c	29.17±7.62e	28.67±4.85
ALT (U/L)	31.83±4.84a	84.67±32.95c	21.17±13.61e	16.67±1.11
GGT (U/L)	5.33±1.49	14.83±3.48c	7.67±1.25e	3.17±0.69
AP (U/L)	130.5±35.75a	268.83±53.25c	69.83±12.21e	56.83±2.67
Prothrombin	75.3±5.4a	58.7±4.3c	74.6±4.9e	102.4±2.7
Time (%)
ATIII (IU)	108.5±14.59	71.67±8.94c	138.50±2.29e	125.0±8.96

^aP<0.05 cirrhosis vs controls;

^cP<0.05 cirrhosis+IBD vs cirrhosis;

^eP<0.05 ATIII vs cirrhosis+IBD.